Argent Biopharma Ltd (ASX: RGT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Argent Biopharma Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Argent Biopharma Ltd (ASX: RGT)
Latest News
⏸️ Investing
MGC Pharmaceuticals Ltd shares plunge 9% lower
⏸️ Investing
Why these 4 ASX shares tumbled lower today
⏸️ Investing
Why these 4 ASX shares have started the week in the red
⏸️ Investing
Why the MGC Pharmaceuticals Ltd share price just doubled in the blink of an eye
⏸️ Investing
Why these 4 ASX shares are ending the week with strong gains
⏸️ Investing
MGC Pharmaceuticals Ltd shares rocket on game-changing deal
⏸️ Investing
Why these 4 ASX shares have started the week with a bang
⏸️ Investing
Why the MGC Pharmaceuticals Ltd share price rocketed 21% today
⏸️ Investing
The horror: Pot stocks collapse 30% in a month
⏸️ Investing
Pot stocks are not winning any brownie points
⏸️ Investing
Pot stocks start the week strongly: Here's what you need to know
⏸️ Investing
Put your life savings in pot stocks – but first, read this
RGT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Argent Biopharma Ltd
MGC Pharmaceuticals Ltd. engages in the production of medical marijuana. Its Endocannabinoid system covers all cells and nerves; it is the messenger of information flowing between immune system and the central nervous system. The company was founded by Nativ Segev on October 21, 2005 and is headquartered in Perth, Australia.
RGT Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 27 Feb 2026 | $0.06 | $0.00 | 0.00% | 132,305 | $0.06 | $0.06 | $0.05 |
| 26 Feb 2026 | $0.06 | $0.00 | 0.00% | 54,472 | $0.06 | $0.06 | $0.06 |
| 25 Feb 2026 | $0.06 | $0.00 | 0.00% | 47,698 | $0.06 | $0.06 | $0.06 |
| 24 Feb 2026 | $0.06 | $-0.01 | -16.13% | 68,059 | $0.06 | $0.06 | $0.05 |
| 23 Feb 2026 | $0.06 | $0.01 | 19.61% | 117,151 | $0.05 | $0.06 | $0.05 |
| 20 Feb 2026 | $0.05 | $0.00 | 0.00% | 27,178 | $0.05 | $0.05 | $0.05 |
| 19 Feb 2026 | $0.05 | $0.00 | 0.00% | 281,626 | $0.06 | $0.06 | $0.05 |
| 18 Feb 2026 | $0.05 | $0.00 | 0.00% | 268,065 | $0.06 | $0.06 | $0.05 |
| 17 Feb 2026 | $0.06 | $0.00 | 0.00% | 44,979 | $0.06 | $0.06 | $0.06 |
| 16 Feb 2026 | $0.06 | $0.00 | 0.00% | 15,500 | $0.06 | $0.06 | $0.06 |
| 13 Feb 2026 | $0.06 | $0.00 | 0.00% | 11,240 | $0.06 | $0.06 | $0.06 |
| 12 Feb 2026 | $0.06 | $0.00 | 0.00% | 10,000 | $0.06 | $0.06 | $0.06 |
| 11 Feb 2026 | $0.06 | $0.00 | 0.00% | 52,639 | $0.06 | $0.06 | $0.06 |
| 10 Feb 2026 | $0.06 | $0.00 | 0.00% | 51,570 | $0.05 | $0.06 | $0.05 |
| 09 Feb 2026 | $0.05 | $0.00 | 0.00% | 14,699 | $0.05 | $0.05 | $0.05 |
| 06 Feb 2026 | $0.05 | $0.00 | 0.00% | 31,771 | $0.05 | $0.05 | $0.05 |
| 05 Feb 2026 | $0.05 | $0.00 | 0.00% | 307,070 | $0.06 | $0.06 | $0.05 |
| 04 Feb 2026 | $0.05 | $0.00 | 0.00% | 29,339 | $0.06 | $0.06 | $0.05 |
| 03 Feb 2026 | $0.05 | $0.00 | 0.00% | 77,708 | $0.05 | $0.06 | $0.05 |
| 02 Feb 2026 | $0.05 | $0.00 | 0.00% | 54,710 | $0.06 | $0.06 | $0.05 |
| 30 Jan 2026 | $0.06 | $0.00 | 0.00% | 195,074 | $0.06 | $0.06 | $0.06 |
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Daniel Robinson | Non-Executive Director | Dec 2023 |
Mr Robinson has over 20 years' experience in multiple corporate roles across stockbroking, corporate advisory, investor relations and governance. He is an experienced Company Secretary and Director of both private and listed companies.
|
| Mr Roby Reuven Zomer | Chief Executive OfficerManaging Director | Feb 2016 |
Mr Zomer has experience in the biopharmaceutical and biotech industries. As the CEO of the company, Roby has demonstrated has driven strategic growth, managed financial operations, and ensured compliance with industry-specific standards. He also served as the Chairman of the Board for Graft Polymer, overseeing the implementation of advanced polymer solutions in the Biotech, Automotive and Recycling sectors. Roby's entrepreneurial background includes founding and leading Green City Urban Recycling, a pioneering Israeli company focused on biofuel production. His work in this field contributed to national energy independence initiatives and led to the company's acquisition by Rafael Advanced Defense Systems. With an industrial engineering and management foundation, Roby Zomer brings a blend of technical and strategic skills to his professional endeavors.
|
| Mr Gary Hermon | Non-Executive Director | Mar 2025 |
Mr Hermon has over 30 years of experience in telecommunications, electrical systems, and infrastructure rollout. Throughout his career, he has managed projects for clients, including Hewlett-Packard, the Victorian Government, BP, and ExxonMobil. At Haumea Pty Ltd, Gary focuses on cable data infrastructure, CCTV systems, and communications networks, ensuring efficient project delivery.
|
| Mr Rowan Harland | Company Secretary | Mar 2023 |
-
|
| Rowan Harland | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| A2 Invest Llc | 11,250,000 | 15.59% |
| Oak Capital Partners Llc | 10,870,718 | 15.06% |
| HSBC Custody Nominees (Australia) Limited | 5,655,176 | 7.83% |
| Group Capital Llc | 3,913,812 | 5.42% |
| Citicorp Nominees Pty Limited | 3,911,828 | 5.42% |
| David Safren | 3,405,016 | 4.72% |
| Shlomie Bierman | 2,230,874 | 3.09% |
| Isamar Margareten | 1,956,906 | 2.71% |
| Yaakov Safren | 1,643,802 | 2.28% |
| Jacob Goldstein | 1,623,072 | 2.25% |
| Yoram Drucker | 1,604,664 | 2.22% |
| Yosef Safren | 1,565,526 | 2.17% |
| Shalom Safren | 1,448,112 | 2.01% |
| Mr Shachar Shimony | 1,371,500 | 1.90% |
| Mrs Yifat Steuer | 1,117,194 | 1.55% |
| Mercer Street Global Opportunity Fund Llc | 836,000 | 1.16% |
| Eliron Yaron | 750,000 | 1.04% |
| A1 Invest Llc | 625,000 | 0.87% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 567,768 | 0.79% |
| Joseph Schwartz | 547,934 | 0.76% |